Feed BAY.WA
BA

Bayer Aktiengesellschaft

BAY.WA · WSE

219.60 zł -0.18% (-0.40 zł)
1M +3.39%
Market Cap 49.7B €
P/E Ratio -
Div. Yield 0.21%
ROE 6.08%

Bulios Fair Price

131.1 zł

40.3% downside

Current Price

219.6 zł

Undervalued Fair Value Overvalued

According to Bulios Fair Price, BAY.WA is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
2/9
Valuation
69 /100
Cheap
EV/EBITDA 9.39x
P/FCF 34.39x
P/S 1.09x
Growth
1 /100
Declining
Rev. growth 3.50%
Book val. growth 12.52%
FCF growth 20.46%
Profitability
42 /100
Moderate
Gross margin 59.05%
FCF margin 3.18%
Net margin 3.82%
Quality
24 /100
Poor
ROIC 8.71%
Asset turnover 0.42x
ROE 6.08%
Debt
31 /100
High
Debt/Equity 1.30x
Net debt/EBITDA 3.82x
Current ratio 1.04x
Stability
56 /100
Moderate
Beta 0.83x
Profitable years 0
Rev. volatility 2.28%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BAY.WA
Online

About the company

Bayer Aktiengesellschaft (BAYN) is a global pharmaceutical and chemical company headquartered in Germany. Bayer focuses on research, development, and manufacturing of pharmaceuticals, agrochemicals, and consumer products. Their portfolio includes medicines for treating various diseases, including cardiovascular diseases, neurological disorders, cancer, among others. Additionally, Bayer produces and distributes a wide range of agrochemical products for plant protection and crop care. The company is also known for its consumer products, such as over-the-counter medications, personal care, household, and veterinary products. Bayer invests in research and development of new drugs, agrochemicals, and innovative technologies to continuously innovate its portfolio and provide effective and safe products to its customers. Bayer Aktiengesellschaft (BAYN) shares are considered an attractive investment for investors seeking a stable and diversified investment in the pharmaceutical and chemical industries with an emphasis on innovation and quality.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Bill Anderson

Employees

88,078

Headquarters

Leverkusen

Upcoming events

03 NOV

Earnings

Upcoming earnings report

48d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.